Results 21 to 30 of about 869,771 (326)
p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis. [PDF]
, 2013 The role of apoptosis in melanoma pathogenesis and chemoresistance is poorly characterized. Mutations in TP53 occur infrequently, yet the TP53 apoptotic pathway is often abrogated.Akslen, Albino, Anissa Chikh, Antonio Costanzo, Arima, Arnoult, Avery-Kiejda, Avery-Kiejda, Azzola, Bae, Baisden, Bardeesy, Belmar-Lopez, Benchimol, Bourne, Brinck, Burford, Bártek, Catherine A. Harwood, Chan, Charlotte M. Proby, Chehab, Chipuk, Chipuk, Choi, Colombari, Daniele Bergamaschi, David Mesher, Dellavalle, Dhillon, Di Como, Dotto, el-Deiry, Fenouille, Flores, Flores, Francesca Moretti, Fukushima, Gembarska, Giovanna Chiorino, Glusac, Gomez-Monterrey, Gressner, Hameed, Harmes, Hibi, Hirao, Hocker, Hoek, Houben, Hu, Hussein, Ikawa, Irene M. Leigh, Jacobs, Ji, Kakudo, Kanner, Kanoko, Karst, Katoh, Keyes, Kilic, Knopf, Koga, Koster, Kulesz-Martin, Lassam, Leverrier, Li, Liefer, Little, MacPartlin, Mancini, Mangiulli, Manuela Graf, Marchenko, Marchini, Maria Scatolini, Massion, Matsuoka, McGregor, Merlino, Michaelis, Mihara, Mills, Moll, Morgan, Mundt, Muthusamy, Müller, Narahashi, Nemajerova, Oda, Okada, Osada, Paolo Sanza’, Perez-Losada, Petitjean, Polsky, Prince, Reis-Filho, Reis-Filho, Ribeiro-Silva, Riley, Rino Cerio, Rocca, Rocco, Rubeta N. Matin, Sakiz, Sansome, Sato, Satyamoorthy, Scatolini, Schilling, Seitz, Senoo, Senoo, Serber, Shieh, Shields, Smalley, Sparrow, Stephanie Law Pak Chong, Stretch, Suh, Tokuyasu, Tuve, Valentina Senatore, Vance, Verhaegen, Walerych, Walerych, Weiss, Westfall, Whitesell, Wäster, Yamamoto, Yamamoto, Yang, Yang, Yaziji, Zangen, Zerp +143 morecore +1 more sourcePre-clinical modeling of cutaneous melanoma
Nature Communications, 2020 Despite the new targeted and immunotherapies for metastatic melanoma, several patients show therapeutic plateau. Here, the authors review the current pre-clinical models of cutaneous melanoma and discuss their strengths and limitations that may help with Vito W. Rebecca, Rajasekharan Somasundaram, Meenhard Herlyn +2 moredoaj +1 more sourceHarnessing autophagy to overcome mitogen‐activated protein kinase kinase inhibitor‐induced resistance in metastatic melanoma [PDF]
, 2019 Background
Patients with malignant melanoma often relapse after treatment with BRAF and/or mitogen‐activated protein kinase kinase (MEK) inhibitors (MEKi) owing to development of drug resistance.Alexander, M., Chaudhry, B., Edwards, N., Hill, David, Lovat, P.E., Plummer, R., Verykiou, S. +6 morecore +1 more sourceThe efficacy of anti‐programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma
Cancer Medicine, 2021 Background Anti‐programmed cell death protein 1 (PD‐1) antibodies are a standard treatment for metastatic melanoma patients. However, the understanding of the efficacy of anti‐PD‐1 for acral melanoma (AM) and mucosal melanoma (MM) is limited as these ...Dai Ogata, Lauren E. Haydu, Isabella C. Glitza, Sapna P. Patel, Hussein A. Tawbi, Jennifer L. McQuade, Adi Diab, Suhendan Ekmekcioglu, Michael K. Wong, Michael A. Davies, Rodabe N. Amaria +10 moredoaj +1 more sourceClinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma
Cancer Medicine, 2019 Background The incidence of melanoma among those of an Asian ethnicity is lower than in Caucasians; few large‐scale Asian studies that include follow‐up data have been reported.Yasuhiro Fujisawa, Shusuke Yoshikawa, Akane Minagawa, Tatsuya Takenouchi, Kenji Yokota, Hiroshi Uchi, Naoki Noma, Yasuhiro Nakamura, Jun Asai, Junji Kato, Susumu Fujiwara, Satoshi Fukushima, Jiro Uehara, Toshihiko Hoashi, Tatsuya Kaji, Taku Fujimura, Kenjiro Namikawa, Manabu Yoshioka, Naoki Murao, Dai Ogata, Kanako Matsuyama, Naohito Hatta, Yoshitsugu Shibayama, Toshiharu Fujiyama, Masashi Ishikawa, Daisuke Yamada, Akiko Kishi, Yoshiyuki Nakamura, Takatoshi Shimiauchi, Kazuyasu Fujii, Manabu Fujimoto, Hironobu Ihn, Norito Katoh +32 moredoaj +1 more sourceAssociation of MC1R Variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study [PDF]
, 2010 <p><b>Background</b> Carrying the cyclin-dependent kinase inhibitor 2A (CDKN2A) germline mutations is associated with a high risk for melanoma. Penetrance of CDKN2A mutations is modified by pigmentation characteristics, nevus phenotypes,Affleck, P, Aguilera, P, Al\uf3s, L, Ancero, A, Arcangeli, F, Argu\ueds, P, Avril, Mf, Avril, Mf, Azizi, E, Badenas, C, Barrett, Jh, Battistuzzi, L, Bergman, W, Bergman, W, Bertazzi, Pa, BIANCHI-SCARR\uc0, G, Bianhi-Scarr\ue0, G, Bishop, Dt, Bishop, Dt, Borg, \uc5, BRESSAC-DE PAILLERETS, B, Bressac-de Paillerets, B, Bruno, W, Bruno, W., Butille, Ja, Calista, D, Calista, D, Campo, A, Capirossi, D, Carrera, C, Carrera, C, Castel, T, Cervera, R, Chan, M, Chaudru, V, Chaudru, V, Conill, C, Corda, E, Cuellar, F, de Lichy, M, Demenais, F, Duffy, Dl, Elder, D, Elder, De, Gabriel, D, Gargiulo, S, Ghiorzo, P, Ghiorzo, P., Gillanders, E, Gliori, S, Goldstein, Am, Goldstein, Am, Gonzalez, M, Gruis, N, Gruis, Na, H\uf6iom, V, H\uf6iom, V, Hansson, J, Hansson, J, Harbst, K, Harland, M, Harland, M, Harrison, J, Haynes, S, Hayward, Nk, Hayward, Nk, Hogg, D, Hogg, D, Holland, Ea, Holland, Ea., Iglesias, P, Iles, Mm, Ingvar, C, Ingvar, C, J\uf6nsson, G, Jeannin, P, Kanetsky, P, Kanetsky, Pa, Karpavicius, B, Kefford, Rf, Kukalizch, K, Landi, G, Landi, Mt, Landi, Mt, Lang, J, Lang, Jm, Leake, S, Lesueur, F, Lind\ue9n, D, Loo, Jc, M\ue5sb\ue4ck, A, Macgregor, S, Mack, T, Mackie, R, Mackie, Rm, Malvehy, J, Mann, Gj, Mann, Gj, Marti-Laborda, R, Martin, Ng, Maubec, E, Melanoma Genetics Consortium: Demenais, F, Mila, M, Ming, M, Ming, Me, Minghetti, P, Mitra, N, Mohamdi, H, Mohamdi, H, Montgomery, Gw, Nasti, S, NEWTON BISHOP JA,, Newton Bishop JA,, Nielsen, K, Njauw, Cj, Njauw, Cn, Ogbah, Z, Olsson, H, Olsson, H, Origone, P, Palmer, J, Palou, J, Parossian, S, Pastorino, L, Pastorino, L, Puig, S, Puig, S, Queirolo, P, RANDERSON-MOOR, J, Randerson-Moor, J, Ruffin, A, Rull, R, S\ue1nchez, M, Schmid, H, Stark, M, Taylor, Jc, Taylor, Y, Tesema, L, Tsao, H, Tsao, H, Tucker, Ma, Tucker, Ma, Tuominen, R, VAN BELLE, P, Van Belle, P, VAN DER VELDEN, P, van der Velden, P, van Mourik, L, van Nieuwpport FA,, Vidal-Sicart, S, Vilalta, A, Vilella, R, Whiteman, Dc, Whittaker, L, Yang, Xr, Yang, Xr +155 morecore +2 more sourcesCo-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma. [PDF]
, 2017 Patients with metastatic uveal melanoma usually die within 1 year of diagnosis, emphasizing an urgent need to develop new treatment strategies. The liver is the most common site of metastasis.Aplin, Andrew E., Cheng, Hanyin, Chua, Vivian, Davies, Michael A., Kageyama, Ken, Liao, Connie, Purwin, Timothy J., Sato, Takami, Terai, Mizue +8 morecore +2 more sourcesmiR-let-7b and miR-let-7c suppress tumourigenesis of human mucosal melanoma and enhance the sensitivity to chemotherapy
Journal of Experimental & Clinical Cancer Research, 2019 Background Mucosal melanoma with poor prognosis is a common histopathologic subtype of melanoma among Chinese and other Asian peoples. Regulated microRNAs (miRNAs) have been reported as oncogenes or tumour suppressors in melanoma.Huan Tang, Meng Ma, Jie Dai, Chuanliang Cui, Lu Si, Xinan Sheng, Zhihong Chi, Longwen Xu, Sifan Yu, Tianxiao Xu, Junya Yan, Huan Yu, Lu Yang, Yan Kong, Jun Guo +14 moredoaj +1 more sourceLabel-free high-throughput photoacoustic tomography of suspected circulating melanoma tumor cells in patients in vivo [PDF]
, 2020 Significance: Detection and characterization of circulating tumor cells (CTCs), a key determinant of metastasis, are critical for determining risk of disease progression, understanding metastatic pathways, and facilitating early clinical intervention.
Cornelius, Lynn A., Hai, Pengfei, Li, Yang, Qu, Yuan, Shmuylovich, Leonid, Wang, Lihong V., Zhu, Liren +6 morecore +1 more source
